4.7 Article

Common viruses associated with lower pediatric multiple sclerosis risk

Journal

NEUROLOGY
Volume 76, Issue 23, Pages 1989-1995

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e31821e552a

Keywords

-

Funding

  1. National Multiple Sclerosis Society
  2. University of California
  3. San Francisco
  4. Stony Brook
  5. Buffalo
  6. University of Alabama Birmingham
  7. Harvard University
  8. Mayo Clinic
  9. NIH [K23NS067055, RR015577, AI082714, U19AI082714, AR053483]
  10. Nancy Davis Foundation
  11. NMSS [RG2901D9/1]
  12. National MS Society
  13. National NS Society
  14. Partners MS Center
  15. Acorda Therapeutics Inc.
  16. Bayer Schering Pharma
  17. Biogen Idec
  18. EMD Serono, Inc.
  19. Genentech, Inc.
  20. Teva Pharmaceutical Industries Ltd.
  21. Novartis
  22. sanofi-aventis
  23. GlaxoSmithKline
  24. MS Association of America
  25. France Foundation
  26. Eli Lilly and Company
  27. MedImmune
  28. Vertex Pharmaceuticals
  29. Wyeth
  30. ZymoGenetics
  31. EPI-Q
  32. Genzyme Corporation
  33. Tibotec Therapeutics
  34. Roche
  35. Johnson Johnson
  36. Janssen
  37. ER Squibb Sons
  38. NIH/NINDS
  39. NIH
  40. Jake Foundation
  41. Children's Guild Foundation
  42. Spinal Muscular Atrophy Foundation
  43. Cooperative International Neuromuscular Research Group/U. S. Department of Education
  44. Pfizer Inc
  45. Mayo Rehabilitation Research Training Center
  46. Conrad Hilton Foundation
  47. Donald and Frances Herdrich Foundation
  48. Canadian MS Society
  49. Morphotek

Ask authors/readers for more resources

Background: Because common viruses are encountered during childhood, pediatric multiple sclerosis (MS) offers a unique opportunity to investigate the influence of these viruses on disease susceptibility and the interactions between seroprevalence and select HLA genotypes. We studied seroprevalence for Epstein-Barr virus (EBV), cytomegalovirus (CMV), and herpes simplex virus (HSV) type 1 and HLA-DRB1*1501/1503 status as predictors of pediatric MS. Methods: This was a retrospective analysis of prospectively collected demographic, clinical, and biologic data in subjects up to 18 years of age with early MS, control subjects seen at the same regional referral pediatric MS clinics, and additional healthy pediatric control subjects. Results: Patients with early pediatric MS (n = 189) and pediatric control subjects (n = 66) were tested. Epstein-Barr nuclear antigen-1 seropositivity was associated with an increased odds of MS (odds ratio [OR] 3.78, 95% confidence interval [CI] 1.52-9.38, p = 0.004) in analyses adjusted for age, sex, race, ethnicity, and HLA-DRB1*1501/1503 status. In multivariate analyses including EBV status, a remote infection with CMV (OR 0.27,95% CI 0.11-0.67, p = 0.004) was associated with a lower risk of developing MS. Although a remote infection with HSV-1 was not associated with an increased odds of MS, a strong interaction was found between HSV-1 status and HLA-DRB1 in predicting MS (p < 0.001). HSV-1 was associated with an increased risk of MS in those without a DRB1*15 allele (OR 4.11, 95% CI 1.17-14.37, p = 0.03), whereas the effect was reversed in those who were DRB1*15-positive (OR 0.07, 95% CI 0.02-0.32, p = 0.001). Conclusions: These findings suggest that some infections with common viruses may in fact lower MS susceptibility. If this is confirmed, the pathways for risk modification remain to be elucidated. Neurology (R) 2011;76:1989-1995

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available